To include your compound in the COVID-19 Resource Center, submit it here.

Reversing Neuropathy

Regenacy’s HDAC6 inhibitor is a disease-modifying therapy for neuropathies

Regenacy Pharmaceuticals LLC is developing the selective histone deacetylase 6 inhibitor ricolinostat as the first disease-modifying therapy for chemotherapy-induced peripheral neuropathy and diabetic neuropathy.

Regenacy was spun out of Acetylon Pharmaceuticals Inc. during its 2016 acquisition by Celgene Corp. with rights to develop ricolinostat in some non-cancer indications. Celgene has ricolinostat in Phase I/II trials to treat lymphoma and multiple

Read the full 600 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers